Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Vinpocetine
45
CHF
CHF 45.00
In stock
AG-CN2-0454-M02020 mgCHF 45.00
AG-CN2-0454-M100100 mgCHF 95.00
AG-CN2-0454-G0011 gCHF 120.00
| Product Details | |
|---|---|
| Synonyms | VPC; (3α,16α)-Eburnamenine-14-carboxylic acid ethyl ester; Ethyl apovincaminate; RGH-4405; TCV 3B; AY 27255 |
| Product Type | Chemical |
| Properties | |
| Formula |
C22H26N2O2 |
| MW | 350.5 |
| Merck Index | 14: 9991 |
| CAS | 42971-09-5 |
| RTECS | JW4792000 |
| Source/Host Chemicals | Semi-synthetic from Voacanga africana. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to slightly yellow crystalline powder. |
| Solubility | Soluble in DMSO, dichloromethane, acetone or 100% ethanol. Insoluble in water. |
| Identity | Determined by 1H-NMR. |
| InChi Key | DDNCQMVWWZOMLN-IRLDBZIGSA-N |
| Smiles | CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +20°C |
| Long Term Storage | +20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Selective Ca2+-calmodulin dependent cGMP-phosphodiesterase (PDE1) inhibitor. Shows vasorelaxant activity.
- Neuroprotective agent.
- Selectively inhibits voltage-sensitive Na2+ channels
- Potent anti-inflammatory agent.
- Inhibitor of NF-κB-dependent inflammatory responses
- Inhibitor of IκB kinase IKK.
- Shown to inhibit the NLRP3 inflammasome.
- Antioxidant. Free radical scavenger.
- Anticancer compound.
- Anticonvulsant.
- Attenuates osteoblastic differentiation of vascular smooth muscle cells.
- Anti-schistosomal agent.
- Attenuates liver fibrosis
Product References
- Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta: H.S. Ahn, et al.; Biochem. Pharmacol. 38, 3331 (1989)
- Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine: J.E. Souness, et al.; Br. J. Pharmacol. 98, 725 (1989)
- Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation: M. Sitges & V. Nekrassov; Neurochem. Res. 24, 1585 (1999)
- In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine: B. Horvath, et al.; Clin. Neuropharmacol. 25, 37 (2002)
- Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons: K. Tarnok, et al.; Neurochem. Int. 53, 289 (2008)
- Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor: R. Deshmukh, et al.; Eur. J. Pharmacol. 620, 49 (2009)
- Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism: K.I. Jeon, et al.; PNAS 107, 9795 (2010)
- Vinpocetine as a potent antiinflammatory agent: A.E. Medina, et al.; PNAS 107, 9921 (2010)
- Vinpocetine inhibits breast cancer cells growth in vitro and in vivo: E.W. Huang, et al.; Apoptosis 17, 1120 (2012)
- Vinpocetine attenuates lipid accumulation and atherosclerosis formation: Y. Cai, et al.; BBRC 434, 439 (2013)
- The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1beta and TNF-alpha expression in rat hippocampus: C.D. Gomez, et al.; J. Neurochem. 130, 770 (2014)
- Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: a review of the literature: L. Zhang & L. Yang; Molecules 20, 335 (2014)
- Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells: R.T. Liu, et al.; Exp. Eye Res. 127, 49 (2014)
- Vinpocetine modulates metabolic activity and function during retinal ischemia: L. Nivison-Smith, et al.; Am. J. Physiol. Cell Physiol. 308, 737 (2015)
- Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-κB: K.W. Ruiz-Miyazawa, et al.; Chem. Biol. Interact. 237, 9 (2015)
- Vinpocetine attenuates osteoblastic differentiation of vascular smooth muscle cells: Y.Y. Ma, et al.; PLoS One 11, e0162295 (2016)
- A comparative study on the anti-schistosomal and hepatoprotective effects of vinpocetine and isosorbide-5-mononitrate on Schistosoma mansoni-infected mice: S.M. Alhusseiny, et al.; Acta Tropica 176, 114 (2017)
- Novel action of vinpocetine in the prevention of paraquat-induced parkinsonism in mice: involvement of oxidative stress and neuroinflammation: I.O. Ishola, et al.; Metab. Brain Dis. 35, 1493 (2018)
- The reduction of XIAP is associated with inflammasome activation in RPE: implications for AMD pathogenesis: J. Gao, et al.; J. Neuroinflamm. 16, 171 (2019)
- Vinpocetine attenuates thioacetamide-induced liver fibrosis in rats: A.E. Elnfarawy, et al. Hum. Exp. Toxicol. ahead of print, 2020
- Updates of Recent Vinpocetine Research in Treating Cardiovascular Diseases: Ch. Zhang & Ch. Yan; J. Cell Immunol. 2, 211 (2020) (Review)
- Vinpocetine protects against the development of experimental abdominal aortic aneurysms: Ch. Zhang, et al.; Clin. Sci. 134, 2959 (2020)
Related Products
